Article
Relationship between CYP2D6 genotype and haloperidol pharmacokinetics and extrapyramidal symptoms in healthy volunteers.
Pharmacogenomics - 1 Oct 2013
Gassó Patricia, Papagianni Katerina, Mas Sergi, de Bobadilla Ramón Fernández, Arnaiz Joan Albert, Bernardo Miquel, Lafuente Amalia
Abstract excerpt
AIM: This study aimed to elucidate the relationship between CYP2D6 genotype and haloperidol pharmacokinetics and induced extrapyramidal symptoms (EPSs). MATERIALS & METHODS: Twenty five healthy subjects were included in this randomized, placebo-controlled, single-dose (5 mg) crossover and double-blind clinical trial, selected according to their CYP2D6 genotype and classified as poor metabolizers (n = 8),...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.